TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03314220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoperative preparation
Description: Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
Study: NCT02555761

Intervention type: DRUG
Intervention: Alcaftadine Ophthalmic Solution 0.25%
Description: Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
Study: NCT02467387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Description: One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: One time infusion 1.5mL/kg
Study: NCT01636752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Online self-help with and without e-mail-support
Study: NCT04612062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE321
Description: CEE321 administered to all subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE321
Description: CEE321 administered to all subjects
Study: NCT04118686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
Description: CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
Study: NCT00744744

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Survey
Study: NCT00163189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
Study: NCT00992563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension
Study: NCT04586933

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (soya)
Description: Placebo (soya)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary guidance
Description: Dietary guidance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary guidance
Description: Dietary guidance
Study: NCT00992563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 10 mg/mL
Study: NCT03008837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Military Field Stimulator
Description: The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
Study: NCT01959685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 125 mg Androxal, 250 mg Androxal separated by at least 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single dose
Study: NCT03132142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-cinnamaldehyde
Description: 1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Menthol
Description: 1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle patch
Description: Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study: NCT01936831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6
Description: Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
Study: NCT03008837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
Study: NCT00688402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose
Study: NCT01936831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
Study: NCT04118686

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
Description: CT program with Computerized cognitive training (CoRe) plus sham stimulation
Study: NCT04504032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
Study: NCT01858155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study: NCT01954303

Intervention type: OTHER
Intervention: Progress of CHD
Study: NCT02039713

Intervention type: DEVICE
Intervention: DeSyne drug eluting stent group
Study: NCT00233519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SomatoKine/IPLEX
Description: Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SomatoKine/IPLEX
Description: Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection.
Study: NCT03445598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive and personalized CCBT
Description: Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feature-limited CCBT
Description: Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Participants will be put on a waitlist for a period of 6 weeks.
Study: NCT02763124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verion-LenSx
Description: The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
Study: NCT02364206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Study: NCT01726140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Mask
Description: the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
Study: NCT02364206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study: NCT02520518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03367494

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of Sweat Chloride and Sweat Bromide
Description: Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
Study: NCT02520518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintenance
Study: NCT00394381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of autologous CIK cells
Description: Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
Study: NCT02520518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ad libitum dietary intake

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad libitum dietary intake

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary restriction
Study: NCT03054077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad with downloaded games
Description: iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
Study: NCT00688402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose
Study: NCT02221596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 50,000IU/wk of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 50,000IU/wk of vitamin D3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic training
Description: 7 days of treadmill training during the 13th week of study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 7 days of treadmill training during the 13th week of study
Study: NCT05261789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turkish Get Up exercise
Description: Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability exercise
Description: After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
Study: NCT02563769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic acid
Description: Clavulanic acid will be administered orally in 250mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic acid
Description: Clavulanic acid will be administered orally in 250mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic acid
Description: Clavulanic acid will be administered orally in 250mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine
Description: 20/40mg Cocaine will be administered by IV
Study: NCT02563769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine
Description: 20/40mg Cocaine will be administered by IV
Study: NCT00788112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study: NCT04709744

Intervention type: DRUG
Intervention: Vitamin D
Description: Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Measure vitamin D level
Study: NCT03659201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosil complete
Description: Oral, during 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantogar
Description: Oral, placebo for 12 weeks and pantogar for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosil
Description: Oral, during only 12 weeks.
Study: NCT00719823

Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
Study: NCT00605904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yohimbine
Description: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mCPP
Description: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mCPP
Description: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)
Study: NCT02247063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
Study: NCT03165149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (A)
Description: patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (B)
Description: patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group (c)
Description: patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
Study: NCT00961636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin (+) laropiprant (ERN/LRPT)
Description: One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin (+) laropiprant (ERN/LRPT)
Description: One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
Study: NCT00788112

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01842308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study: NCT04657952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block
Description: Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.